Study on the efficacy of octreotide acetate for cancer-related bowel obstruction

UMIN ID: UMIN000000521

Registered date:14/11/2006

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: cancer-related bowel obstruction
• Date of first enrollment: 2006/10/01
• Target sample size: 50
• Countries of recruitment: Japan
• Study type: Interventional
• Intervention(s): Octreotide acetate of 300 ug/day is administered primarily as a continuous subcutaneous infusion using a continuous infusion pump. Dosage is fixed at 300 ug/day until Day 4. In patients extubated by Day 4, dosage is fixed at 300 ug/day until Day 7.

Outcome(s)

• Primary Outcome: Amelioration of abdominal symptoms (subjective parameters)
• Secondary Outcome: 1) Reduction in the number of vomiting episodes and the volume of drainage from a gastric tube (Objective parameters) 2) Correlation between subjective and objective parameters 3) Differences in the efficacy of treatment with octreotide acetate among different cancer types or obstruction sites 4) Assessment of safety in octreotide acetate therapy

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: Not applicable
• Gender: Male and Female
• Exclude criteria: 1)Patients with cognitive dysfunction 2)Patients with esophageal obstruction 3)Patients with symptomatic brain metastases or meningeal dissemination 4)Patients undergoing anticancer treatment or radiotherapy within the last 2 weeks 5)Patients judged by the physician in charge to be unsuitable for this study

Related Information

• Primary Sponsor: University of Tsukuba
• Source(s) of Monetary Support: University of Tsukuba